Earnings Feed
Start Free
First Tracks Biotherapeutics, Inc.·4

Jun 17, 4:05 PM ET

FENTON DENNIS M 4

Research Summary

AI-generated summary

Updated

First Tracks (TRAX) Director Dennis Fenton Receives 6,030 Shares

What Happened
Dennis M. Fenton, a director of First Tracks Biotherapeutics, had 6,030 restricted stock units (RSUs vest) convert to 6,030 shares on June 15, 2026. The Form 4 shows an exercise/conversion of a derivative (code M) acquiring 6,030 shares at $0.00 and a corresponding derivative disposition entry; no cash was paid and no open‑market sale is reported.

Key Details

  • Transaction date: June 15, 2026; Form 4 filed June 17, 2026 (timely filing).
  • Reported prices: $0.00 per share (RSU settlement for no consideration). Total reported cash value: $0.
  • Shares affected: 6,030 RSUs converted to 6,030 common shares.
  • Shares owned after transaction: not specified in the provided excerpt of the filing.
  • Footnotes: F1 notes each RSU converts to one share for no consideration; F2 states 100% of the RSUs vested on June 15, 2026, subject to continued service.
  • Transaction code: M (exercise or conversion of a derivative instrument — here RSU settlement).

Context
RSU vesting is a compensation event that converts restricted units into stock and is not the same as a market purchase or sale; it does not by itself signal a buy or sell decision. The filing shows conversion of compensation awards into shares rather than an open‑market trade.